Cell News and Research

RSS

Johns Hopkins researchers discover oxaliplatin-based nerve damage

Oxaliplatin, a platinum-based anticancer drug that's made enormous headway in recent years against colorectal cancer, appears to cause nerve damage that may be permanent and worsens even months after treatment ends.

29 Sep 2011

Scientists discover effective target to kill late-stage metastatic prostate cancer cells

Purdue University scientists believe they have found an effective target for killing late-stage, metastatic prostate cancer cells.

29 Sep 2011

Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin in metastatic pancreatic cancer.

29 Sep 2011

First developmental study of human neural stem cells in subventricular zone

Researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center have identified a new pathway of stem cell activity in the brain that represents potential targets of brain injuries affecting newborns.

29 Sep 2011

SanBio initiates SB623 Phase 1/2a clinical trial in ischemic stroke

SanBio, Inc. has announced that a patient at Stanford University Medical Center has become the first to be treated with SB623, a novel cell therapy for patients with disability resulting from ischemic stroke.

29 Sep 2011

Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV

Phase I clinical trials developed by Spanish Superior Scientific Research Council (CSIC) together with Gregorio Mara--n Hospital in Madrid and Cl-nic Hospital in Barcelona, reveals MVA-B preventive vaccine's immune efficiency against Human's immunodeficiency virus (HIV).

28 Sep 2011

YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis

YM BioSciences Inc. today announced that it has enrolled the first patients in its multi-center Phase II trial of CYT387 administered twice-daily (BID) for the treatment of myelofibrosis.

28 Sep 2011

Some stroke patients may benefit from treatment outside the typical 3 hour window

Stroke victims may have a longer window of opportunity to receive treatment to save their brain cells, demonstrates a literature review published by University of Alberta medical researchers in Lancet Neurology.

28 Sep 2011

Researchers validate two parasite enzymes as potential anti-malarial drug targets

Researchers at the Perelman School of Medicine at the University of Pennsylvania, Monash University, and Virginia Tech have used a set of novel inhibitors to analyze how the malaria parasite, Plasmodium falciparum, uses enzymes to chew up human hemoglobin from host red blood cells as a food source.

28 Sep 2011

New method for quickly identifying individual viruses

A new method for quickly identifying individual viruses and recognising how they bind to host cells may become a vital tool in the early control of winter vomiting disease and other virus-based diseases. In the west, this means saving money and reducing stress on health-care systems. In developing countries, this means saving lives.

28 Sep 2011

Study sheds light on when to start antiretroviral therapy

Findings from a study published in the current issue of the journal Archives of Internal Medicine, when "taken together with other studies published over the last few years," show that beginning people living with HIV on highly active antiretroviral therapy (HAART) when their CD4 cell count is between 350 and 500 "appears to be beneficial over the long term.

28 Sep 2011

Scientists identify proteasome phosphatase that appears to regulate removal of damaged proteins

A study by scientists at the University of California, San Diego and UC Irvine has identified an enzyme called a proteasome phosphatase that appears to regulate removal of damaged proteins from a cell. The understanding of how this process works could have important implications for numerous diseases, including cancer and Parkinson's disease.

28 Sep 2011

Close link between SF3B1 mutation and specific feature of myelodysplastic syndromes

Geneticists have discovered that a gene involved in the modification of ribonucleic acid (RNA) is mutated in a significant proportion of people with a collection of blood cancers called myelodysplastic syndromes.

27 Sep 2011

Lead compound activates infection-fighting REDD1 protein and kills flu strain

A compound tested by UT Southwestern Medical Center investigators destroys several viruses, including the deadly Spanish flu that killed an estimated 30 million people in the worldwide pandemic of 1918.

27 Sep 2011

Scientists uncover how methylation changes can influence blood stem cell's fate

Scientists at Cold Spring Harbor Laboratory (CSHL) and the University of Southern California (USC) have uncovered intriguing new evidence helping to explain one of the ways in which a stem cell's fate can be determined.

27 Sep 2011

Researchers identify frequent SF3B1 gene mutation in myelodysplasia

A genomic study of chronic blood cancer - a precursor to leukaemia - has discovered gene mutations that could enable diagnosis using only a blood test, avoiding the need for an invasive and painful bone marrow biopsy.

27 Sep 2011

Weill Cornell receives NIH's T-R01 Award for spina bifida research

The National Institutes of Health (NIH) has awarded a five-year, $5.5 million Transformative Research Project (T-R01) Award to fund research into risk factors for spina bifida and related congenital defects in which an area of the affected baby's spine or brain is not fully enclosed.

27 Sep 2011

University of Zurich receives AICR grant to improve vaccines against Burkitt's lymphoma

Research in Switzerland could help reduce the time taken to develop vaccines against cancer tumours.

27 Sep 2011

Eating blueberries may inhibit breast cancer tumor growth

Eating blueberries may inhibit breast cancer tumor growth, according to a recent study by researchers at the City of Hope in Los Angeles that is published in the October 2011 issue of The Journal Of Nutrition and featured in the September issue of Food Nutrition & Science.

27 Sep 2011

Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.

27 Sep 2011

Cell News and Research

Johns Hopkins researchers discover oxaliplatin-based nerve damage

Scientists discover effective target to kill late-stage metastatic prostate cancer cells

Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer

First developmental study of human neural stem cells in subventricular zone

SanBio initiates SB623 Phase 1/2a clinical trial in ischemic stroke

Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV

YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis

Some stroke patients may benefit from treatment outside the typical 3 hour window

Researchers validate two parasite enzymes as potential anti-malarial drug targets

New method for quickly identifying individual viruses

Study sheds light on when to start antiretroviral therapy

Scientists identify proteasome phosphatase that appears to regulate removal of damaged proteins

Close link between SF3B1 mutation and specific feature of myelodysplastic syndromes

Lead compound activates infection-fighting REDD1 protein and kills flu strain

Scientists uncover how methylation changes can influence blood stem cell's fate

Researchers identify frequent SF3B1 gene mutation in myelodysplasia

Weill Cornell receives NIH's T-R01 Award for spina bifida research

University of Zurich receives AICR grant to improve vaccines against Burkitt's lymphoma

Eating blueberries may inhibit breast cancer tumor growth

Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News